David Berg, MD, discusses his meta-analysis of 3 major trials of dapagliflozin, which determined its efficacy in reducing cardiovascular death risk.
David Berg, MD
Advertisement
David Berg, MD, is a cardiologist and critical care specialist at Brigham and Women’s Hospital and a member of the TIMI Study Group.
Articles by David Berg, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
3
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
4
Q&A: Zasocitinib Response in the Scalp, Nails, Palms and Soles
5